Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 13 de 13
Filter
1.
J Popul Ageing ; : 1-23, 2022 Mar 29.
Article in English | MEDLINE | ID: mdl-35368880

ABSTRACT

Background: The aging population is increasingly faced with daily life limitations, threatening their Functional Independence (FI). These limitations extend different life domains and require a broad range of community-care professionals to be addressed. The Decision Support Tool for Functional Independence (DST-FI) facilitates community-care professionals in providing uncontradictory recommendations regarding the maintenance of FI in community-dwelling older people. The current study aims to determine the validity and reliability of the DST-FI. Methods: Sixty community-care professionals completed a twofold assessment. To assess construct validity, participants were asked to assign predefined recommendations to fifty cases of older people to maintain their level of FI. Hypotheses were tested regarding the expected recommendations per case. Content validity was assessed by questions on relevance, comprehensiveness, and comprehensibility of the current set of recommendations. Twelve participants repeated the assessment after two weeks to enable both within- and between rater reliability properties, expressed by an Intraclass Correlation Coefficient. Results: Seven out of eight predefined hypotheses confirmed expectations, indicating high construct validity. As the recommendations were indicated 'relevant' and 'complete', content validity was high as well. Agreement between raters was poor to moderate while agreement within raters was moderate to excellent, resulting in moderate overall reliability. CONCLUSION: The DST-FI suggests high validity and moderate reliability properties when used in a population of community-dwelling older people. The tool could facilitate community-care professionals in their task to preserve FI in older people. Future research should focus on psychometric properties like feasibility, acceptability, and developing and piloting strategies for implementation in community-care.

2.
J Plast Reconstr Aesthet Surg ; 62(8): e286-9, 2009 Aug.
Article in English | MEDLINE | ID: mdl-18166508

ABSTRACT

Adverse reactions following BCG vaccination are uncommon, with an estimated prevalance of 0.4 per 1000 vaccines [Lotte A, Wasz-Hockert O, Poisson N, et al. Second IUATLD study on complications induced by intradermal BCG vaccination. Bull Int Union Tuber 1988;63:47-59]. Complications include erythema, blistering, abscess formation, regional lymphadenitis and keloid formation. The onset of cutaneous tuberculosis (TB) has also been reported. We describe the case of 12-year-old girl who developed extensive primary ulceration involving most of her left upper arm at the site of a BCG vaccination. A skin graft to the arm failed to take at the periphery and the ulcerated area increased to involve most of the upper lateral arm. Over a period of 18 months, secondary lesions developed on her forehead prompting further investigation of a systemic disease process. Following extensive immunological and microbiological examination, a diagnosis of vaccine-induced granulomatous vasculitis was made and the patient responded to a combination of antituberculous therapy and steroids. Once the disease process was under control, skin grafting of the ulcerated area was successful in achieving wound closure. Non-healing ulceration may be referred to the plastic surgeon and a diagnosis of vasculitis should be considered in difficult cases. A multidisciplinary team approach involving immunologists, dermatologists and plastic surgeons provides the best opportunity for a successful long-term outcome in terms of disease control as well as immediate skin cover.


Subject(s)
Adjuvants, Immunologic/adverse effects , BCG Vaccine/adverse effects , Skin Ulcer/etiology , Upper Extremity/pathology , Vasculitis/etiology , Child , Female , Forehead , Humans , Skin Transplantation/methods , Skin Ulcer/therapy , Vasculitis/therapy
3.
Ned Tijdschr Geneeskd ; 152(45): 2457-63, 2008 Nov 08.
Article in Dutch | MEDLINE | ID: mdl-19051798

ABSTRACT

OBJECTIVE: To determine the association between overweight, physical and mental health conditions and health-related quality of life in an adult community population upon entering a new primary care practice. DESIGN: Cross-sectional study. METHOD: Baseline data from 4825 participants (mean age: 39 years; 55% women) in the Utrecht Health Project; a dynamic primary care population study with a response rate of over 50%, were used to determine and compare the prevalence of diagnosed medical conditions, complaints and quality of life between individuals of normal weight (BMI 18.5-< 25 kg/m2) and those who were overweight (BMI 25-< 30 kg/m2) or obese (BMI > or = 30 kg/m2). Normal weight was used as the reference category. RESULTS: Overweight individuals were approximately twice as likely to have cardiovascular risk factors and had a 20-60% increased risk of back pain, arthrosis, migraine, dyspepsia and respiratory symptoms than those of normal weight. Obese individuals were almost twice to four times more likely to have these conditions and were additionally at increased risk of obstructive pulmonary disease, cardiovascular disease and arthritis (range of odds ratios (ORs): 1.9-3.3). Somatization and reduced physical well-being were more common among both overweight (ORs: 1.2-1.5) and obese (ORs: 1.7-3.7) individuals, whereas only obese individuals demonstrated a 30-50% increased risk of mental health conditions and reduced mental well-being. CONCLUSION: Overweight was associated with a broad range of physical and mental health conditions and a reduced health-related quality of life. Routine measurement of BMI upon entering a primary care practice is relatively simple and may contribute to the identification of individuals at high risk of comorbidity.


Subject(s)
Mental Health , Obesity/epidemiology , Obesity/psychology , Overweight/epidemiology , Overweight/psychology , Quality of Life , Adult , Body Mass Index , Case-Control Studies , Comorbidity , Cross-Sectional Studies , Female , Humans , Male , Netherlands/epidemiology , Obesity/mortality , Overweight/mortality , Risk Factors , Thinness/epidemiology , Thinness/mortality , Thinness/psychology
4.
Ann Rheum Dis ; 63(12): 1576-80, 2004 Dec.
Article in English | MEDLINE | ID: mdl-15547081

ABSTRACT

OBJECTIVE: To examine variables associated with bone mineral density (BMD) in patients with rheumatoid arthritis (RA). METHODS: We investigated 373 patients with low to moderately active RA. Patients with low disease activity were recruited from a cohort of patients in clinical remission. Patients with moderately active disease were included in a trial comparing the effects of long term high intensity exercise programme and conventional physical therapy. Demographic and clinical data were collected. Bone mineral density (BMD) was measured by means of dual x ray absorptiometry (DXA). Associations between demographic and clinical measurements on the one hand and BMD on the other were investigated in regression analyses. RESULTS: The patient group consisted of middle aged, mainly female, patients. The median (interquartile range) disease duration was 7 (4 to 13) years, the mean disease activity score (standard deviation) was 3.2 (1.4). Of the group, 66% was rheumatoid factor positive, and 83% (n = 304) had never used corticosteroids. The median Larsen score of hands and feet was 27 (5 to 61). Greater age and low body mass index were related to low BMD at the hip and spine. High Larsen score for hands and feet was significantly associated with low BMD at the hip. The use of corticosteroids was not independently associated with BMD. The results of the multiple regression analyses also applied to the subgroup of corticosteroid naive patients. CONCLUSION: BMD data of patients with low to moderately active RA demonstrated an association between high radiological RA damage and low BMD at the hip, which suggests an association between the severity of RA and the risk of generalised bone loss, which also occurred in corticosteroid naive patients.


Subject(s)
Arthritis, Rheumatoid/complications , Bone Density , Osteoporosis/etiology , Adrenal Cortex Hormones/therapeutic use , Adult , Aged , Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Arthritis, Rheumatoid/physiopathology , Body Mass Index , Female , Femur Neck/physiopathology , Humans , Linear Models , Lumbar Vertebrae/physiopathology , Male , Middle Aged , Severity of Illness Index
5.
Ann Rheum Dis ; 61(4): 351-3, 2002 Apr.
Article in English | MEDLINE | ID: mdl-11874840

ABSTRACT

BACKGROUND: Several studies have reported an association between the presence of the shared epitope (SE) and susceptibility to rheumatoid arthritis (RA). Recent studies have shown that certain HLA-DRB1 alleles in combination with predisposing DQB1 and DQA1 alleles may protect against the development of RA. This model is known as the rheumatoid arthritis protection (RAP) hypothesis. OBJECTIVE: To determine the distribution of HLA-DRB1 and DQB1/DQA1 alleles in a cohort of patients with RA in remission and to determine the association between these HLA alleles and the persistence of remission. PATIENTS AND METHODS: HLA-DRB1 and DQB1 typings were performed in 167 patients with RA in remission, defined according to the American College of Rheumatology criteria. The disease course, as defined by the persistence of remission during a follow up of two years, was compared between subgroups. According to the RAP hypothesis patients were divided into three subgroups: patients carrying predisposing DQ alleles, patients carrying predisposing alleles in combination with protective alleles (DQ(RA+)/DERAA phenotype), and patients lacking the predisposing alleles. According to the SE hypothesis, patients were divided into three subgroups based on whether they were carrying two, one, or no predisposing alleles (SE alleles). RESULTS: Predisposing DQ alleles along with a DERAA-bearing allele were present in 14 (8%) of the 167 patients. At least one SE allele was present in 116 (69%) patients; 34 of them (20%) were carrying two copies. The disease course was not significantly different between the subgroups according to the SE and RAP hypothesis, respectively. CONCLUSION: The frequency of DQ(RA+)/DERAA combinations and of SE alleles in patients with RA clinically in remission was similar to that found in other RA populations. Persistent remission of RA was not associated with any particular HLA subtypes, indicating that HLA typing is not useful for predicting persistent clinical remission.


Subject(s)
Arthritis, Rheumatoid/genetics , HLA-DQ Antigens/genetics , HLA-DR Antigens/genetics , Polymorphism, Genetic/genetics , Antirheumatic Agents/therapeutic use , Arthritis, Rheumatoid/drug therapy , Cohort Studies , Genotype , HLA-DQ beta-Chains , HLA-DRB1 Chains , Humans , Middle Aged , Remission Induction
6.
J Rheumatol ; 28(9): 1967-74, 2001 Sep.
Article in English | MEDLINE | ID: mdl-11550961

ABSTRACT

OBJECTIVE: To investigate the effects of doxycycline on disease activity and joint destruction in patients with rheumatoid arthritis (RA). METHODS: A 36 week double blind, placebo controlled crossover trial was conducted. Patients (n = 66) received 50 mg doxycycline or placebo twice a day during 12, 24, or 36 weeks. Patient assessments were performed before the treatment was administered, at 6, 12, 24 and 36 weeks of treatment, and finally at 4 weeks after cessation of treatment. Patient assessments, swollen and tender joint counts, duration of morning stiffness, erythrocyte sedimentation rate, and Modified Disease Activity Score were used as measures of disease activity. Effects on joint destruction were assessed by urinary excretion of the pyridinolines hydroxylysylpyridinoline and lysylpyridinoline and by scoring radiographic damage of hands and feet before and after treatment. RESULTS: The changes of clinical or laboratory disease activity measures, pyridinoline excretion, or progression of radiographic joint damage during doxycycline or placebo treatment did not differ significantly. CONCLUSION: The results indicate that 50 mg doxycycline twice a day provided no therapeutic benefit for patients with RA.


Subject(s)
Arthritis, Rheumatoid/diagnosis , Arthritis, Rheumatoid/drug therapy , Doxycycline/administration & dosage , Adolescent , Adult , Aged , Aged, 80 and over , Analysis of Variance , Chi-Square Distribution , Cross-Over Studies , Dose-Response Relationship, Drug , Double-Blind Method , Doxycycline/adverse effects , Drug Administration Schedule , Female , Follow-Up Studies , Humans , Male , Middle Aged , Pain Measurement , Reference Values , Severity of Illness Index , Treatment Failure , Treatment Outcome
7.
Arthritis Rheum ; 44(5): 997-1002, 2001 May.
Article in English | MEDLINE | ID: mdl-11352263

ABSTRACT

OBJECTIVE: Complement activation in patients with rheumatoid arthritis (RA) is considered to be triggered by immune complexes. Recently, it was shown that C-reactive protein (CRP) can activate the complement system in vivo. We therefore hypothesized that part of the complement activation in RA is due to CRP. The aim of this study was to investigate CRP-mediated complement activation in RA, and to assess its correlation with disease activity. METHODS: Complexes between CRP and the activated complement components C3d (C3d-CRP) and C4d (C4d-CRP), which reflect CRP-mediated complement activation, as well as the overall levels of activated C3 and C4 were measured in the plasma of 107 patients with active RA and 177 patients with inactive RA. Inactive RA was defined according to the American College of Rheumatology criteria for clinical remission. Disease activity was assessed by the modified Disease Activity Score (DAS28). RESULTS: Plasma levels of C3d-CRP and C4d-CRP were increased in the majority of the patients, and were significantly higher in patients with active disease versus those with inactive RA (P < 0.001). In patients with active RA, the plasma concentrations of C3d-CRP and C4d-CRP correlated significantly with the DAS28 (Spearman's rho 0.61 and 0.55, respectively; P < 0.001), whereas these correlations were less pronounced in patients with inactive RA (Spearman's rho 0.28 [P < 0.001] and 0.25 [P = 0.001], respectively). Levels of activated C3 and C4 were also increased in the majority of the patients, particularly in patients with active RA. CONCLUSION: Part of the activation of complement in RA is mediated by CRP and is correlated with disease activity. We suggest that this activation is involved in the pathogenesis of RA.


Subject(s)
Arthritis, Rheumatoid/immunology , Arthritis, Rheumatoid/metabolism , C-Reactive Protein/immunology , C-Reactive Protein/metabolism , Complement Activation/immunology , Adolescent , Adult , Aged , Aged, 80 and over , Complement C3b/immunology , Complement C3b/metabolism , Complement C3c/immunology , Complement C3c/metabolism , Complement C4/immunology , Complement C4/metabolism , Complement C4b/immunology , Complement C4b/metabolism , Female , Humans , Male , Middle Aged , Peptide Fragments
8.
J Rheumatol ; 28(4): 911-3, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11327275

ABSTRACT

The smallest detectable difference (SDD) reflects that component of a measure statistically attributable to error from the measurement process itself. As such it is an irreducible component of the inherent variability in measurements in clinical trials and will affect their design, whether randomized or observational. Even though the application of the SDD concept to assaying radiographs in rheumatoid arthritis is relatively new and not well understood, systematic work on the influences of radiographic SDD can be done. This report describes the effects of a number of clinical aspects of the disease and operational aspects of trials on the values of the SDD of radiographic progression data. We show that if conditions affecting SDD are known and kept constant across datasets, the SDD of radiological progression from one study may be generalizable to other studies. However, if any one condition varies, the SDD is distinctly unrobust and cannot be generalized to other studies.


Subject(s)
Arthritis, Rheumatoid/diagnostic imaging , Arthrography/methods , Disease Progression , Humans , Randomized Controlled Trials as Topic
9.
Rheumatology (Oxford) ; 39(7): 742-4, 2000 Jul.
Article in English | MEDLINE | ID: mdl-10908692

ABSTRACT

OBJECTIVE: Clinical remission occurs in 10-20% of patients with rheumatoid arthritis (RA). However, it is questionable whether clinical remission corresponds to the complete absence of the inflammatory process. To answer this question we measured collagen degradation products (which are known to be increased in active disease) in patients with inactive RA and in healthy controls. PATIENTS AND METHODS: The urinary levels of bone resorption markers (pyridinoline, deoxypyridinoline, N-terminal telopeptide and C-terminal telopeptide) were measured in 184 patients with inactive RA, as defined by the preliminary criteria of clinical remission of the American College of Rheumatology, and in 118 healthy individuals. RESULTS: After adjusting for age, concentrations of all four bone resorption markers were found to be significantly higher in patients with inactive RA than in healthy controls. CONCLUSION: The urinary excretion of bone resorption markers is increased in patients classified as having inactive RA. These results suggest that the inflammatory process is not completely absent.


Subject(s)
Amino Acids/urine , Arthritis, Rheumatoid/urine , Bone Resorption/urine , Bone and Bones/metabolism , Adult , Aged , Aged, 80 and over , Arthritis, Rheumatoid/therapy , Biomarkers/urine , Collagen/urine , Collagen Type I , Female , Humans , Male , Middle Aged , Peptides/urine , Remission Induction
10.
Curr Opin Rheumatol ; 12(2): 91-8, 2000 Mar.
Article in English | MEDLINE | ID: mdl-10751011

ABSTRACT

Outcome assessment in rheumatic disorders is getting more and more attention. A series of Outcome Measures in Rheumatology (OMERACT) conferences has provided a good impulse for further research in the field. In this chapter we will review the results of the last OMERACT 4 conference in detail. This conference was focused on longitudinal/observational studies, rheumatoid arthritis (response criteria and imaging), and core sets for ankylosing spondylitis and systemic lupus erythematosus. Moreover, an overview of recent literature on measures of disease activity, quality of life measures, and imaging is presented. For the various rheumatic disorders, several new instruments and/or further validation steps are described.


Subject(s)
Rheumatic Diseases/physiopathology , Consensus Development Conferences as Topic , Humans , Prognosis
11.
J Rheumatol ; 26(3): 746-8, 1999 Mar.
Article in English | MEDLINE | ID: mdl-10090195

ABSTRACT

A plenary radiograph reading session was conducted prior to the rheumatoid arthritis imaging group sessions to familiarize participants with radiograph scoring methods and their problems, and to introduce the concept of measurement error. After brief reviews on how to score radiographs using the Larsen and Sharp method, photographic slides of metacarpophalangeal joints of 2 patients were shown. Participants were asked to register their absolute scores on paper, and their progression scores on an interactive voting keypad, allowing immediate visualization of the results. The objectives of the session were clearly met, as evidenced by lively discussions in the groups. Participant mean scores agreed well with the expert scores. Sharp scores showed wider scatter between participants than Larsen scores. This was only partially explained by the greater score range inherent in the method. In addition, participants needed more time to score according to Sharp than Larsen. Participants were sensitized to the challenges of radiographic measurement of damage.


Subject(s)
Arthritis, Rheumatoid/diagnostic imaging , Arthrography/methods , Rheumatology/methods , Disease Progression , Humans , Metacarpophalangeal Joint/pathology , Observer Variation , Severity of Illness Index
12.
J Rheumatol ; 26(3): 749-51, 1999 Mar.
Article in English | MEDLINE | ID: mdl-10090196

ABSTRACT

None of the current scoring methods for radiological damage in rheumatoid arthritis (RA) is ideal. The objective for RA imaging at OMERACT IV was to start discussion about the problems and applicability of the current scoring methods for radiological damage and to start discussion on the challenge of new imaging techniques. The RA imaging module comprised preconference reading material, plenary sessions, small group discussions, and a plenary report of the group sessions, combined with interactive voting. The OMERACT filter guided the discussions. Priorities for further research in imaging studies were: (1) pathologies versus features on radiographs; (2) relation with longterm outcome; and (3) definition of minimum clinically important difference.


Subject(s)
Arthritis, Rheumatoid/diagnostic imaging , Rheumatology/methods , Arthritis, Rheumatoid/therapy , Arthrography , Disease Progression , Health Planning Guidelines , Humans , Magnetic Resonance Imaging , Reproducibility of Results , Severity of Illness Index , Treatment Outcome
13.
J Pharm Biomed Anal ; 13(3): 255-63, 1995 Mar.
Article in English | MEDLINE | ID: mdl-7619885

ABSTRACT

A liquid chromatographic (LC) procedure using alumina as stationary phase in both the pre- and the analytical column, is reported for the determination of WR1065, the active metabolite of the amino- and thiol-containing anticancer drug WR2721. After pre-column derivatization of the thiol group, the analyte is determined by LC with diode laser induced fluorescence detection in the near-infrared. Selective removal of excess label is achieved by means of column switching; it allows the detection of 5 x 10(-9) M WR1065 in water and 10-fold diluted, deproteinated plasma samples. The detection limit is determined by the derivatization reaction and not by the fluorescence detection of the labelled analyte. Endogeneous thiols do not interfere.


Subject(s)
Antineoplastic Agents/analysis , Mercaptoethylamines/analysis , Radiation-Protective Agents/analysis , Antineoplastic Agents/blood , Antineoplastic Agents/urine , Chromatography, Thin Layer , Humans , Hydrogen-Ion Concentration , Indicators and Reagents , Lasers , Mercaptoethylamines/blood , Mercaptoethylamines/urine , Spectrometry, Fluorescence , Temperature
SELECTION OF CITATIONS
SEARCH DETAIL
...